This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2015
  • /
  • 05
  • /
  • GSK 2696273 is filed at EMA to treat adenosine dea...
Drug news

GSK 2696273 is filed at EMA to treat adenosine deaminase severe combined immunodeficiency syndrome (ADA-SCID)- GSK

Read time: 1 mins
Last updated:7th May 2015
Published:7th May 2015
Source: Pharmawand

GSK, Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) announced the submission of a marketing application to the European Medicines Agency (EMA) for a gene therapy (GSK 2696273) to treat patients with a rare disease, adenosine deaminase severe combined immunodeficiency syndrome (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.

Adenosine deaminase severe combined immunodeficiency syndrome- ADA-SCI. is an ultra rare disease in which patients cannot make lymphocytes (a type of white blood cell) and, as a result, have a severely deficient immune system. An estimated 14 children in Europe are born each year with the condition. A faulty gene inherited from both parents stops production of an essential protein called adenosine deaminase (ADA), which is particularly important for the formation of lymphocytes and a functioning immune system. Children born with ADA-SCID have an impaired ability to fight off everyday infections resulting in severe and life-threatening illness. They rarely survive beyond 1-2 years unless immune function is restored.

Comment; This ultra-rare white blood cell deficiency condition often referred to as ‘bubble boy disease’.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights